Apollomics Inc. (NASDAQ:APLM – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 1,592 shares, a decline of 51.2% from the May 14th total of 3,260 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 10,971 shares, the days-to-cover ratio is presently 0.1 days.
Apollomics Stock Performance
APLM opened at $13.83 on Friday. Apollomics has a twelve month low of $3.66 and a twelve month high of $42.12. The business has a 50 day moving average price of $14.27 and a 200 day moving average price of $17.17.
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded shares of Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
Hedge Funds Weigh In On Apollomics
An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent filing with the Securities and Exchange Commission. 19.13% of the stock is currently owned by institutional investors and hedge funds.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
Further Reading
- Five stocks we like better than Apollomics
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
- TJX: Retail’s Apex Predator Feasts on Inflation
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
